Public Health, Department of Social Medicine, Osaka University Graduate School of Medicine.
Department of Public Health and Preventive Medicine, Faculty of Medicine, Minia University.
J Epidemiol. 2019 Mar 5;29(3):104-109. doi: 10.2188/jea.JE20170123. Epub 2018 Aug 4.
Limited evidence is available on the association of insulin-like growth factors (IGFs) and risk of heart failure in population-based samples. We investigated whether serum IGFs concentrations can predict mortality from heart failure.
We conducted a nested case-control study of 39,242 subjects aged 40-79 years who participated in the JACC study, a large Japanese prospective cohort study; participants provided serum samples and were followed up for 9 years. In heart failure cases and age-, sex-, community-, and year of blood withdrawal-matched controls, we measured serum concentrations of IGF-I, IGF-II, and IGF binding protein 3 (IGFBP3) and transforming growth factor (TGF-β1).
During the follow-up, there were 88 heart failure deaths (44 men and 44 women). Each increment of 1 standard deviation [SD] of IGF-II (120.0 ng/mL in women and 143.7 ng/mL in men) was associated with a 47% reduced risk of mortality from heart failure; multivariable odds ratio was 0.53 (95% confidence interval [CI], 0.30-0.94, P-trend = 0.03). The multivariable odds ratio in the highest quartile of IGFBP3 serum concentrations (≥3.29 µg/mL in women and ≥3.31 µg/mL in men) compared with the lowest (<2.11 µg/mL in women and <2.56 µg/mL in men) was 0.24 (95% CI, 0.05-1.11; P-trend = 0.12). No association was found between serum concentrations of IGF-I or TGF-β1 and risk of heart failure.
Higher serum concentrations of IGF-II were associated with lower mortality from heart failure, which might suggest a possible role of IGF-II in the occurrence or prognosis of heart failure.
人群样本中,关于胰岛素样生长因子(IGFs)与心力衰竭风险的关联,现有证据有限。我们研究了血清 IGFs 浓度是否可以预测心力衰竭的死亡率。
我们对参加 JACC 研究的 39242 名年龄在 40-79 岁的受试者进行了巢式病例对照研究,JACC 研究是一项大型日本前瞻性队列研究;参与者提供了血清样本,并随访了 9 年。在心力衰竭病例和年龄、性别、社区和采血年份匹配的对照组中,我们测量了血清 IGF-I、IGF-II 和 IGF 结合蛋白 3(IGFBP3)和转化生长因子(TGF-β1)的浓度。
在随访期间,有 88 例心力衰竭死亡(44 例男性和 44 例女性)。IGF-II 的每一个标准差(SD)增加[女性为 120.0ng/ml,男性为 143.7ng/ml]与心力衰竭死亡率降低 47%相关;多变量优势比为 0.53(95%置信区间 [CI],0.30-0.94,P 趋势=0.03)。IGFBP3 血清浓度最高四分位数(女性≥3.29μg/ml,男性≥3.31μg/ml)与最低四分位数(女性<2.11μg/ml,男性<2.56μg/ml)相比,其多变量优势比为 0.24(95%CI,0.05-1.11;P 趋势=0.12)。IGF-I 或 TGF-β1 血清浓度与心力衰竭风险之间无关联。
较高的 IGF-II 血清浓度与心力衰竭死亡率降低相关,这可能表明 IGF-II 在心力衰竭的发生或预后中可能发挥作用。